Could a Two-Drug combo finally cure chronic hepatitis b?

This study tests whether adding a PD-1 antibody (sintilimab) and pegylated interferon to standard antiviral therapy can cure chronic hepatitis B. The goal is to eliminate the hepatitis B surface antigen (HBsAg) from the blood, which would mean the virus is no longer active. The study involves 45 adults who have been on stable antiviral treatment for at least a year and have low but detectable HBsAg levels. Participants will be monitored for 48 weeks to see if the combination therapy leads to a functional cure without the need for lifelong medication.